# SAPPHIRE (NCT03906071)

> Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: sitravatinib plus nivolumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03906071
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Interventions: Nivolumab; Sitravatinib; Docetaxel
- Enrollment: 577
- Primary outcome: Overall Survival (OS)

## Indexed commentary on SAPPHIRE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sapphire-nct03906071